Clinical Trial Update: Pixantrone (BBR 2778) in Patients With Refractory Acute Myelogenous Leukemia (AML) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of pixantrone (BBR 2778) in refractory acute myeloid leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Pixantrone (pixantrone)

Snippet

Sponsor: CTI BioPharma | Conditions: Acute Myelogenous Leukemia | Phase 1, Phase 2 | Status: COMPLETED